Cymabay Therapeutics Overview
Valuation check: CBAY's ROE is -38.21%, below the Healthcare sector average of 29.39%.
Get informed when a big investor buys or sells
+ Follow-38.21%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Cymabay Therapeutics (CBAY) currently reports a ROE of -38.21%. That is below the Healthcare sector average of 29.39%. Use the charts on this page to explore Cymabay Therapeutics's ROE history and peer comparisons.
Cymabay Therapeutics's ROE of -38.21% is lower than the Healthcare sector average of 29.39%. That is roughly 230.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Cymabay Therapeutics's current -38.21% should be judged against Healthcare norms (sector average: 29.39%) and against CBAY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -38.21%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Cymabay Therapeutics, and consider following CBAY for alerts when major investors trade the stock.
Cymabay Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -38.21% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CBAY with unrelated industries.
